Microdosing psychedelics involves consuming doses that are one-twentieth to one-tenth the size of standard doses. The practice has become increasingly popular among individuals seeking to boost their productivity, elevate their mood, or treat symptoms of depression, anxiety, or pain. The increasing use of microdosing has inspired media coverage and scientific analysis of its costs and benefits. On April 13, POPLAR will gather experts on the science, law, and business of microdosing for a panel discussion accompanied by a digital symposium on the Bill of Health. After a keynote address by Dr. James Fadiman, a longtime microdosing scholar and advocate, the event will turn to a panel discussion of the promise, risks, and future of microdosing psychedelics.

Panelists
Introduction: Carmel Shachar, Executive Director, The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School

Sarah Hashkes, Co-Founder & CEO, Radix Motion; Chief Technology Innovation Officer, Red Light Holland

Dave Kopilak, Shareholder, Emerge Law Group

Erin Sharoni, Chief Product Officer, FOXO Technologies; Candidate for Master of Bioethics, Harvard Medical School

Ifetayo Harvey, Founder, People of Color Psychedelic Collective

Moderator: Mason Marks, MD, JD, Assistant Professor of Law, University of New Hampshire Franklin Pierce School of Law; Senior Fellow and Project Lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School

Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.